Healthcare - Biotechnology - NASDAQ - US
$ 3.64
0.276 %
$ 690 M
Market Cap
-8.47
P/E
Price Target
Average
--100.00%
Revenue Forecast
Estimate
32.79%
EBIT
Estimate
7.81%
Net Income
Estimate
14.92%
WALL STREET ESTIMATES
Wall Street Analysts Price Targets
Arbutus Biopharma Corporation
ABUS has no price targets from Wall Street.
REVENUE FORECAST
Revenue Forecast Chart ABUS
EBIT FORECAST
EBIT Forecast Chart ABUS
NET INCOME FORECAST
Net Income Chart ABUS